TM
UTMD icon

Torren Management’s Utah Medical Products UTMD Stock Holding History

Torren Management’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14
Closed -$783 – 1440
2025
Q4 		$783 Buy
+14
New +$812 ﹤0.01% 1248

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Torren Management's UTMD Position: Q1 2026 in Review

Torren Management sold out of Utah Medical Products (UTMD) in Q1 2026, closing a stake of 14 shares — an estimated $783 sold.

Torren Management first reported a position in UTMD in Q4 2025 and held it in 1 quarter. The position peaked at $783 in Q4 2025. 119 funds tracked by Wall St. Rank hold UTMD as of Q1 2026.

  • Torren Management reported no remaining Utah Medical Products position as of Q1 2026 after selling out during the quarter.
  • Torren Management sold 14 Utah Medical Products shares in Q1 2026, an estimated $783.
  • Torren Management first reported a position in Utah Medical Products in Q4 2025 and held it in 1 quarter.
  • Torren Management's Utah Medical Products position peaked at $783 in Q4 2025.
  • 119 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.